Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...

Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

Sopra Steria is one of the only five providers to achieve a Best-in-class overall rating in 2024 as supplier of ServiceNow-related servicesPAC highlighted Sopra Steria's ability to extend ServiceNow ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...

This was the stock's second consecutive day of losses.

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

The stock's fall snapped a three-day winning streak.

Regeneron Pharmaceuticals has a 1 year low of $642.00 and a 1 year high of $1,211.20. The firm has a market capitalization of $79.35 billion, a PE ratio of 17.87, a price-to-earnings-growth ratio ...

As of January 28, 2025, the average one-year price target for Regeneron Pharmaceuticals is $1,022.63/share. The forecasts range from a low of $570.65 to a high of $1,291.50.